Table 10.
Applications of PBPK in predicting ADMET properties from 2016 to 2018.
Year | Tool | Compound /Preparations | Properties | References |
---|---|---|---|---|
2016 | GastroPlus | Alectinib | Oral bioavailability, Aqueous solubility, Cmax, AUC | Parrott et al., 2016 |
2016 | GastroPlus | Bisoprolol, Nifedipine, Cimetidine, Furosemide | Oral absorption | Hansmann et al., 2016 |
2016 | GastroPlus | Carvedilol loaded nanocapsules (CLN) | AUC, Cmax | George et al., 2016 |
2016 | GastroPlus | Ketoconazole, Erythromycin | AUC, Cmax | Boetsch et al., 2016 |
2016 | GastroPlus | Levofloxacin | logP, Plasma protein binding, AUC, Cmax | Zhu et al., 2016 |
2016 | GastroPlus | Met XR 1000 mg tablets | Dose, logD, AUC, Cmax | Chen W. et al., 2016 |
2016 | PKSim | Azathioprine | Hepatotoxicity | Thiel et al., 2016 |
2016 | PKSim | Morphine and Furosemide | Vss value | Schlender et al., 2016 |
2016 | WinNonlin | 6-chloro-9-nitro-5-oxo-5H-benzo-(a)-phenoxazine (CNOB) | AUC, Vd, CL, half-life | Wang J. H. et al., 2016 |
2016 | WinNonlin | Arbekacin | Vd | Hagihara et al., 2016 |
2016 | WinNonlin | Busulfan (BU) | AUC, apparent clearance | de Castro et al., 2016 |
2016 | WinNonlin | Cetuximab (CTX), Capecitabine (CCB) | Cmax, AUC, Vd | Rachar et al., 2016 |
2016 | WinNonlin | Glibenclamide | CL, Vd, half-life | Rambiritch et al., 2016 |
2016 | WinNonlin | Imatinib mesylate | Bioavailability, Tmax, Cmax | Arora et al., 2016 |
2016 | WinNonlin | Midazolam | Cmax, Vd | Vuu et al., 2016 |
2016 | WinNonlin | Midazolam, Irinotecan | Clearance rate | Lee et al., 2016 |
2016 | WinNonlin | Perfluorooctanoic acid (PFOA), Perfluorooctanesulfonic acid (PFOS), Perfluorohexane sulfonic acid (PFHxS) | AUC, renal clearance, Cmax, Vd | Kim et al., 2016 |
2016 | WinNonlin | Propofol | Plasma concentrations, Vd | Chen J. Y. et al., 2016 |
2016 | WinNonlin | Sodium succinate, Polysorbate, Arginine, Phosphate-buffered saline (PBS) | CL, Half-life, Cmax | Gupta et al., 2016 |
2016 | WinNonlin | Tacrine hydrochloride | Skin penetration | Patel et al., 2016 |
2016 | WinNonlin | Tilmicosin | AUC, Cmax | Zhang et al., 2016 |
2016 | WinNonlin | Treosulfan (TREO) | Cmax, AUC | Romanski et al., 2016 |
2017 | WinNonlin | Tacrolimus | Plasma clearance | David-Neto et al., 2017 |
2017 | GastroPlus | Basmisanil | logD, Solubility | Yang et al., 2017 |
2017 | GastroPlus | Buagafuran | Plasma Protein Binding, logP | Yang et al., 2017 |
2017 | GastroPlus | Compound A (CPD A) | Bioavailability, Cmax, AUC | Stillhart et al., 2017 |
2017 | GastroPlus | Mangiferin | Aqueous solubility, logD, logP, Permeability | Khurana et al., 2017 |
2017 | PKSim | Cefazolin, Cefuroxime, Cefradine | CL | Dallmann et al., 2017 |
2017 | PKSim | Endogenous IgG | CL, Vd | Niederalt et al., 2017 |
2017 | PKSim | Fentanyl, Alfentanil, Thiopental, Omadacycline, Amiodarone, Propylthiouracil | Plasma concentration | Pilari et al., 2017 |
2017 | PKSim | Vorinostat | Dose | Moj et al., 2017 |
2017 | WinNonlin | Acetylkitasamycin | Cmax, Tmax, AUC | Nan et al., 2017 |
2017 | WinNonlin | Benznidazole | Cmax, AUC | Molina et al., 2017 |
2017 | WinNonlin | Ceftiofur | CL, Vd | Wang J. et al., 2017 |
2017 | WinNonlin | Cloxacillin | Dose | Burmanczuk et al., 2017 |
2017 | WinNonlin | Danofloxacin | AUC | Zhang N. et al., 2017 |
2017 | WinNonlin | Diaveridine | Oral bioavailability, Cmax, AUC | Li Y. F. et al., 2017 |
2017 | WinNonlin | Enrofloxacin | Plasma concentration | Shan et al., 2017 |
2017 | WinNonlin | Iohexol | CL | Zhang C. et al., 2017 |
2017 | WinNonlin | Lurasidone | Cmax, AUC | Hu et al., 2017 |
2017 | WinNonlin | Meropenem | Plasma concentration | Kong et al., 2017 |
2017 | WinNonlin | Metolazone | AUC, Cmax, Tmax | Li X. et al., 2017 |
2017 | WinNonlin | Psilocybin | Nephrotoxicity | Brown et al., 2017 |
2017 | WinNonlin | Pyrazinamide | Cmax | Voelkner et al., 2017 |
2017 | WinNonlin | Sarafloxacin | Dose | Yu et al., 2017 |
2017 | WinNonlin | Sildenafil | CL, Tmax, Vd | Olguin et al., 2017 |
2017 | WinNonlin | Tenofovir | CL, Plasma concentration | Du X. et al., 2017 |
2017 | WinNonlin | Tilmicosin | AUC, Tmax, half-life | Zhang L. et al., 2017 |
2017 | WinNonlin | Treosulfan | Liver, Brain toxicity | Romanski et al., 2017 |
2017 | WinNonlin | Tulathromycin | Dose | Zhou et al., 2017 |
2018 | GastroPlus | Cefadroxil | Permeability, logP, Aqueous solubility, Distribution volume | Hu and Smith, 2018 |
2018 | GastroPlus | Compound-A | Bioavailability, logP, Permeability, Aqueous solubility | Kou et al., 2018 |
2018 | GastroPlus | Dasatinib | AUC, Cmax, Tmax | Vaidhyanathan et al., 2018 |
2018 | GastroPlus | DPP-4 inhibitors | Bioavailability | Daga et al., 2018 |
2018 | GastroPlus | Lanabecestat (AZD3293) | Bioavailability | Ye et al., 2018 |
2018 | GastroPlus | Tramadol | Renal clearance | T'Jollyn et al., 2018 |
2018 | PKSim | Carvedilol | Plasma concentration | Ibarra et al., 2018 |
2018 | PKSim | Escitalopram | Plasma exposure | Delaney et al., 2018 |
2018 | PKSim | Indomethacin, Felodipine | Plasma exposure | Keemink et al., 2018 |
2018 | PKSim | Pregabalin | Plasma concentrations | Idkaidek et al., 2018b |
2018 | WinNonlin | Cefquinome | Cmax, AUC | Shan et al., 2018 |
2018 | WinNonlin | Dexmedetomidine | CL, Vd | Song et al., 2018 |
2018 | WinNonlin | Gentamicin | AUC | Gestrich et al., 2018 |
2018 | WinNonlin | Gliclazide | Vd, CL | Shaik et al., 2018 |
2018 | WinNonlin | Letrozole | Dose | Arora et al., 2018 |
2018 | WinNonlin | Moxidectin | CL, Tmax, Cmax | Xiao et al., 2018 |
2018 | WinNonlin | Penicillin G | Vd, CL, half-life | Padari et al., 2018 |
2018 | WinNonlin | Seroquel XR, Quesero XR | AUC, Cmax, CL | Huang et al., 2018 |
2018 | WinNonlin | Sitagliptin | Cmax, Tmax, AUC, T1/2 | Sangle et al., 2018 |
2018 | WinNonlin | Vitacoxib | Plasma concentrations, Cmax, AUC | Wang et al., 2018a |
2018 | WinNonlin | Amoxicillin/clavulanic acid tablets | Cmax, Tmax, AUC, T1/2 | De Velde et al., 2018 |
2018 | WinNonlin | Phenylbutyric acid (PBA), phenylacetic acid (PAA), and phenylacetylglutamine (PAGN), UPAGN | Plasma concentrations, AUC, Tmax | Berry et al., 2018 |
2018 | WinNonlin | Siponimod | T1/2 | Jin et al., 2018 |
2018 | WinNonlin | Lacosamide | T1/2, Vd, Cmax, CL, AUC | Franquiz et al., 2018 |
2018 | WinNonlin | Tildipirosin (TD) | Cmax, AUC, Tmax | Wang et al., 2018b |
2018 | WinNonlin | Streptomycin | T1/2, AUC, Tmax, Cmax | Chen and Gao, 2018 |
2018 | WinNonlin | Pantoprazole | T1/2, AUC, Vd/F, CL/F | Shakhnovich et al., 2018 |
2018 | WinNonlin | FVIII concentrates | T1/2 | Cheng X. et al., 2018 |
2018 | WinNonlin | Adherence to tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) | Cmax, AUC | Ibrahim et al., 2018 |
2018 | WinNonlin | Valsartan, Hydrochlorothiazide (HCT) | Cmax, Tmax, AUC, T1/2, Kel | Idkaidek et al., 2018a |
2018 | WinNonlin | Individual total serum cortisol, unbound serum cortisol and salivary cortisone | Cmax, AUC, Tmax, Bioavailability | Johnson et al., 2018 |
LogP, octanol-water partition coefficient; LogD, octanol-water distribution coefficient; AUC, area under the curve; Cmax, peak concentration; Vss, steady-state; Vd, volume of distribution; T1/2, half-life; logP, octanol-water partition coefficient; logD, octanol-water distribution coefficient; CL, clearance; CL/F, body clearance corrected for bioavailability; Vd/F, volume of distribution corrected for bioavailability. Kel, elimination rate constant; F, bioavailability; Tmax, time to maximum concentration.